© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Mereo BioPharma Group plc (MREO) shows an Average True Range (ATR) of 0.29 and an Enterprise Value of 337.89M. Its average trading volume over the past 3 months is 5.53M, indicating liquidity. These fundamental metrics provide insight into MREO's underlying financial health and market activity.
Mereo BioPharma Group plc (MREO) technical indicators as of December 30, 2025: the SMA 20 is -85.83%, SMA 50 at -85.28%, and SMA 200 at -86.35%. The RSI 14 value is 19.02, suggesting its current momentum. These technical analysis signals help assess MREO's price trends and potential future movements.
Mereo BioPharma Group plc (MREO) stock performance overview as of December 30, 2025: The 52-week high is $3.84 (currently -92.57% below), and the 52-week low is $0.2 (currently -80.59% above). Over the past year, MREO's performance is N/A, compared to the S&P 500's 10.62% change.
According to market data, Mereo BioPharma Group plc (MREO) stock's recent performance metrics show that over the last month, MREO is -84.06%, with a Year-to-Date (YTD) performance of -91.85%. Over the past year, the stock has seen a N/A change. These figures summarize MREO's price movements across various periods, reflecting its historical returns.
According to current financial data, MREO stock's P/E (TTM) ratio is -7.45, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for MREO, including P/S (235.78), P/B (6.82), and P/FCF (-11.20), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.